Batch: SIL220F011A in stock

1. Description of product
Protein concentration (mg/mL) 20
Volume per vial (μL/vial) 150
Protein content per vial (mg/vial) 3.0
Cap color (depends on the product)
SIL000 SIL210 SIL220 SIL230 SIL250 SIL260 SIL270 SIL240 SIL200
green red red yellow pink yellow red white blue
Phase I dependent activities(Vmax) ACTIVITY ENZYME Substrate (Concentration (µM))
Phenacetin O-deethylation CYP1A2 Phenacetin 200 μM
Bupropion hydroxylation CYP2B6 Bupropion 300 μM
Amodiaquine N-deethylation CYP2C8 Amodiaquin 20 μM
Diclofenac 4’-hydroxylation CYP2C9 Diclofenac 200 μM
Mephenytoin hydroxylation CYP2C19 (S)-Mephenytoin 60 μM
Dextromethorphan O-demethylation CYP2D6 Dextromethorphan 20 μM
Chlorzoxazone 6-hydroxylation CYP2E1 Chlorzoxazone 200 μM
Testosterone 6β-hydroxylation CYP3A4 Testosterone 75 μM
Nifedipine oxidation CYP3A4 Nifedipine 50 μM
2. Product characterisation

Phase I dependent activities (Vmax) (pmol x min-1 x mg-1 protein)

Activity Enzyme Result % inhibition
Phenacetin O-deethylation CYP1A2 550.0 6.0
Coumarin 7-hydroxylation CYP2A6 25.0 95.0
Bupropion hydroxylation CYP2B6 195.0 25.0
Amodiaquine N-deethylation CYP2C8 690.0 5.0
Diclofenac 4’-hydroxylation CYP2C9 666.0 11.0
Mephenytoin hydroxylation CYP2C19 16.0 17.0
Dextromethorphan O-demethylation CYP2D6 122.0 10.0
Chlorzoxazone 6-hydroxylation CYP2E1 2809.0 6.0
Testosterone 6β-hydroxylation CYP3A4 616.0 5.0
Nifedipine oxidation CYP3A4 503.0 4.0
Midazolam 1’-hydroxylation CYP3A4 1887.0 12.0
3. Conditions of storage and delivery
Date of manufacture June 3, 2019
Storage temperature -80.0 °C
Delivery In dry ice
Last control date September 8, 2019
Expiry date June 3, 2025
Date of batch release October 27, 2020